Vaxart Bags $453M Worth BARDA-Funded Project, Seeks To Raise $40M Via Equity Offering
Vaxart Bags $453M Worth BARDA-Funded Project, Seeks To Raise $40M Via Equity Offering
Vaxart, Inc. (NASDAQ:VXRT) shares traded higher in the premarket session on Friday, up more than 23% at one point.
Vaxart（纳斯达克：VXRT）股票在周五盘前交易中上涨超过23％，一度超过流通时高点。
Vaxart's average session volume was about 1.6 million. Friday premarket's session volume had exceeded four million at the time of writing.
Vaxart的平均交易量约为160万。周五盘前交易时段的成交量已超过400万。
Yesterday, Vaxart obtained a project award worth $453 million through the Rapid Response Partnership Vehicle, supported by the Biomedical Advanced Research and Development Authority under the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services.
昨天，Vaxart通过“快速应对伙伴关系车辆”获得了价值4.53亿美元的项目奖励，该项目得到了美国卫生与公共服务部（HHS）战略准备和应对管理局支持的生物医学先进研发局的支持。
The funding from the award will be disbursed in two installments, with an initial sum of about $65.7 million accessible immediately to facilitate ongoing study start-up endeavors.
来自该奖项的资金将分两次拨付，首笔约6570万美元可立即使用以促进正在进行的研究启动工作。
These funds are designated for conducting a Phase 2b comparative study, which will assess Vaxart's oral pill COVID-19 vaccine candidate against an FDA-approved mRNA vaccine comparator.
这些资金专用于进行2b期比较研究，将评估Vaxart的口服COVID-19疫苗候选药物与FDA批准的mRNA疫苗比较器进行比较。
Vaxart expects to commence enrollment as soon as summer 2024, with a potential interim analysis of vaccine efficacy compared to an approved mRNA comparator by the first quarter of 2025.
Vaxart预计最快于2024年夏季开始招募，到2025年第一季度可能会对疫苗有效性与批准的mRNA比较器进行中期分析。
This funding from BARDA will assist us in determining whether we can bring a transformational, next-generation approach to global vaccination," said Steven Lo, Vaxart's Chief Executive Officer.
“BARDA的这笔资金将有助于我们确定是否可以将全球疫苗接种引入变革，”Vaxart首席执行官Steven Lo表示。
That's not all!
这还不是全部！
Vaxart also announced an underwritten offering of 50 million shares of its common stock at an offering price of $0.80 per share. This represents a premium of over 6% to the last closing price of $0.75 per share.
Vaxart还宣布发行5000万股普通股的认购价为0.80美元/股的认购书，这相当于每股0.75美元的上一个收盘价格的溢价超过6％。
The offering by Vaxart is anticipated to generate gross proceeds of approximately $40 million prior to deductions for underwriting discounts, commissions, and estimated offering expenses.
Vaxart的发行预计将在扣除承销折扣，佣金和估计的发行费用之前产生约4000万美元的募集资金。
It is projected to conclude around June 17, 2024, pending standard closing conditions.
预计将在标准结算条件下于2024年6月17日左右结束。
Price Action: VXRT shares are trading lower by 7.68% to $0.69 at last check on Friday.
股价走势：截至上周五最后一次查询，VXRT股价下跌7.68％至0.69美元。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.November 18th, 2023
免责声明本内容部分由人工智能工具生成，并经Benzinga编辑审核和发布。2023年11月18日